© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
pan-serotype dengue virus NS4B inhibitor
oral preclin. candidate, trial planned
From 1.5M cmpd phenotypic screen + opt.
Sci. Transl. Med., Feb. 3, 2021
Novartis (NITD), Emeryville, CA
14. The Novartis pan-serotype dengue virus (DENV) NS4B protein inhibitor, NITD-688, is a preclinical candidate with strong activity against all four serotypes of DENV in vitro and excellent oral…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.